Boehringer Ingelheim Venture Fund

AgomAb, a Belgian biotherapeutics company, has secured 21 million euros in Series A funding. V-Bio Ventures and Advent France Biotechnology led the round with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.

Acousia Therapeutics said May 14 that it raised 10 million euros ($11.9 million) in a Series B round led by LBBW Venture Capital and joined by new investors Creathor Ventures and Bregua Corp. Boehringer Ingelheim Venture Fund (BIVF) and Kreditanstalt für Wiederaufbau also participated in the round. Acousia, of Tubingen, German, is developing therapies for inner ear-related diseases and pathologies.

Metabomed Ltd, an Israeli company developing drugs that target cancer metabolism, announced it has completed an extension of its Series A round from new and existing investors, bringing its total haul to $18 million. The new investors are Pfizer Inc and Arkin Holdings. They join existing investors MS Ventures, Boehringer Ingelheim Venture Fund, Pontifax Fund and the Technion Research and Development Foundation.

Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund (BIVF) and Portage Biotech Inc, a Toronto-based developer of pharmaceutical and biotech products. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.

Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund USA Inc and Portage Biotech Inc. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.

ViraTherapeutics GmbH said Wednesday it raised 3.6 million euros (US$4 million) in a first close of a Series A financing round. Boehringer Ingelheim Venture Fund and EMBL Ventures co-led the round, while Austria Wirtschaftsservice through its Venture-Capital-Initiative also invested. Innsbruck, Austria-based ViraTherapeutics is biopharmaceutical company developing cancer immunotherapies.

Belgium-based Promethera Biosciences, a biotech firm that focuses on treating liver diseases, has closed its Series C round at $31.4 million. The investors included SFPI-FPIM, Vesalius Biocapital, Boehringer Ingelheim Venture Fund and SMS Investments.

Rigontec GmbH said Tuesday it raised €9.45 million (US$11.95 million) in a first close of a Series A round co-led by Wellington Partners and Boehringer Ingelheim Venture Fund. Other investors include NRW Bank and High-Tech Gründerfonds. Rigontec, a biopharmaceutical company, is developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Montreal-based diagnostics company Optina has secured $2.1 million in funding from the diagnostics accelerator at the Alzheimer's Drug Discovery Foundation.

Brainomix, an AI-powered medtech solutions company, has raised $21.5 million in funding.

The round was led by Canada's Lumira Ventures and US-based B Capital Group with participation from LYZZ Capital and all the company's Series A investors.

Montreal-based Optina Diagnostics, which is focused on retinal imaging, brain health and systemic disease detection, has raised C$24.8 million in Series A financing.

Abalos Therapeutics, an immuno-biotherapeutics company that targets cancer cells, has secured a $50 million extension to its Series A round.

The French life sciences firm announces a first close of its second fund at €86m ($102m).

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing.

Delonix Bioworks Ltd, a biotechnology company, has raised $14 million in financing.